Immunotherapies Using Fully Human Polyclonal Antibodies Without Need for Convalescent Plasma Blood Donors with Eddie Sullivan SAb Biotherapeutics

Eddie Sullivan, President, CEO, Co-Founder, SAb Biotherapeutics talks about their innovative technology to generate targeted highly potent immunotherapies on a large scale.  SAb is producing fully human polyclonal antibodies targeted to COVID-19 without the need for convalescent plasma blood donations by using genetically engineered cattle which produce the fully human antibodies.

@SABBantibody 

#COVID19 #immunotherapies #antibodies

SAbbiotherapeutics.com/covid-19

Download the transcript here